Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Gossamer Bio (GOSS) EBITDA (2022 - 2025)

Historic EBITDA for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to -$48.2 million.

  • Gossamer Bio's EBITDA fell 4835.77% to -$48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.0 million, marking a year-over-year decrease of 11708.57%. This contributed to the annual value of -$55.0 million for FY2024, which is 6938.13% up from last year.
  • Per Gossamer Bio's latest filing, its EBITDA stood at -$48.2 million for Q3 2025, which was down 4835.77% from -$42.5 million recorded in Q2 2025.
  • Gossamer Bio's 5-year EBITDA high stood at $49.3 million for Q2 2024, and its period low was -$59.4 million during Q3 2022.
  • In the last 4 years, Gossamer Bio's EBITDA had a median value of -$42.5 million in 2023 and averaged -$39.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 21598.69% in 2024, then crashed by 18620.85% in 2025.
  • Quarter analysis of 4 years shows Gossamer Bio's EBITDA stood at -$55.8 million in 2022, then increased by 14.12% to -$47.9 million in 2023, then surged by 38.16% to -$29.6 million in 2024, then tumbled by 62.92% to -$48.2 million in 2025.
  • Its last three reported values are -$48.2 million in Q3 2025, -$42.5 million for Q2 2025, and -$38.7 million during Q1 2025.